S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:XENTIntersect ENT Stock Price, Forecast & News

$20.49
-0.90 (-4.21 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.35
Now: $20.49
$21.69
50-Day Range
$12.10
MA: $16.79
$21.39
52-Week Range
$5.97
Now: $20.49
$31.46
Volume328,200 shs
Average Volume728,369 shs
Market Capitalization$670.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Read More
Intersect ENT logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.14 million
Book Value$3.75 per share

Profitability

Net Income$-42,990,000.00

Miscellaneous

Employees393
Market Cap$670.06 million
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$20.49
-0.90 (-4.21 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

How has Intersect ENT's stock been impacted by COVID-19?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XENT stock has decreased by 4.7% and is now trading at $20.49.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Intersect ENT?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intersect ENT
.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Intersect ENT
.

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) announced its quarterly earnings results on Tuesday, August, 4th. The medical equipment provider reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.15. The medical equipment provider earned $9.78 million during the quarter, compared to analyst estimates of $7.87 million. Intersect ENT had a negative return on equity of 55.81% and a negative net margin of 71.96%. The firm's revenue was down 63.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.36) earnings per share.
View Intersect ENT's earnings history
.

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, June, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.665-7.998 million, compared to the consensus revenue estimate of $4.13 million.

What price target have analysts set for XENT?

9 brokers have issued 12-month price objectives for Intersect ENT's stock. Their forecasts range from $10.00 to $30.00. On average, they expect Intersect ENT's share price to reach $19.07 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts' price targets for Intersect ENT
.

Has Intersect ENT been receiving favorable news coverage?

Media coverage about XENT stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intersect ENT earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Intersect ENT
.

Are investors shorting Intersect ENT?

Intersect ENT saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,130,000 shares, an increase of 56.0% from the April 15th total of 724,200 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.6% of the shares of the company are sold short.
View Intersect ENT's Short Interest
.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
  • Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
  • Ms. Christine R. Kowalski, Chief Operations Officer (Age 62)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (6.73%), Jennison Associates LLC (1.95%), Assenagon Asset Management S.A. (0.79%), Goldman Sachs Group Inc. (0.71%), Great Lakes Advisors LLC (0.68%) and Mutual of America Capital Management LLC (0.47%). Company insiders that own Intersect ENT stock include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Robert H Binney, Jr, Susan P Stimson and Thomas A West.
View institutional ownership trends for Intersect ENT
.

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Goldman Sachs Group Inc., SG Americas Securities LLC, Spark Investment Management LLC, Blair William & Co. IL, Dupont Capital Management Corp, and State of Wisconsin Investment Board.
View insider buying and selling activity for Intersect ENT
.

Which institutional investors are buying Intersect ENT stock?

XENT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mutual of America Capital Management LLC, Mackay Shields LLC, WINTON GROUP Ltd, Russell Investments Group Ltd., Great Lakes Advisors LLC, First Quadrant L P CA, and Aigen Investment Management LP. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $20.49.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $670.06 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.